Insider and congress filings
Merck & Co., Inc. (MRK)
About Merck & Co., Inc.
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Robert Davis
- Employees
- 74,000
- Listed since
- -
- Market value
- $364.5B
- Price to earnings
- 117.1
- Earnings per share
- $1.28
- Dividend yield
- 2.28%
Earnings
6 reported quarters · next on Oct 29, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 4, 2026 | -$0.13 | -$0.27 | $16.6B | $16.4B | EPS beatRevenue in line |
| Q1 FY2026reported Apr 30, 2026 | -$1.28 | -$1.47 | $16.3B | $15.8B | EPS beatRevenue beat |
| Feb 3, 2026 | $2.04 | $2.01 | $16.4B | $16.2B | EPS in lineRevenue in line |
| Q3 FY2025reported Oct 30, 2025 | $2.58 | $2.36 | $17.3B | $17.0B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 29, 2025 | $2.13 | $2.03 | $15.8B | $15.9B | EPS beatRevenue in line |
| Q1 FY2025reported Apr 24, 2025 | $2.22 | $2.13 | $15.5B | $15.3B | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 8, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Robert M. DavisChairman, Chief Executive Officer and President | $1.6M | $12.1M | $7.0M | $20.8M |
| Dean Li, M.D., Ph.D.Executive Vice President and President, Merck Research | $1.5M | $4.3M | $3.1M | $8.9M |
| Caroline LitchfieldExecutive Vice President and Chief Financial Officer | $1.2M | $3.6M | $2.8M | $7.5M |
| Jennifer ZacharyExecutive Vice President and General Counsel | $1.1M | $2.7M | $2.1M | $5.9M |
| Sanat ChattopadhyayExecutive Vice President and President, Merck Manufact | $982K | $2.4M | $2.1M | $5.4M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $29.2B | 226,999,837 | +0.5% | 9.18% |
| Vanguard Capital Management LLC | $20.7B | 161,323,174 | +0.2% | 6.53% |
| State Street Corp | $15.6B | 120,413,256 | +0.9% | 4.87% |
| Wellington Management Group LLP | $11.1B | 86,249,283 | +2.3% | 3.49% |
| Vanguard Portfolio Management LLC | $8.7B | 67,738,969 | +0.6% | 2.74% |
| Geode Capital Management, LLC | $7.8B | 60,744,214 | +2.0% | 2.46% |
| Charles Schwab Investment Management Inc | $7.0B | 54,365,289 | +9.2% | 2.20% |
| Sixth Street Partners Management Company, L.P. | $7.0B | 54,365,289 | +100.0% | 2.20% |
| Morgan Stanley | $6.3B | 48,641,158 | +2.1% | 1.97% |
| FMR LLC | $5.8B | 45,440,355 | +2.1% | 1.84% |
| Jpmorgan Chase & Co | $5.7B | 43,886,420 | -17.2% | 1.78% |
| Fisher Asset Management, LLC | $4.9B | 38,516,263 | +45.7% | 1.56% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
9 filings of 331 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Chirfi GuindoEVP, Access, Policy & Comms | Sold | 10,000 | $135.00 | $1.4M | Aug 13, 2026 | 0d |
| Jennifer ZacharyEVP, General Counsel | Sold | 80,315 | $133.46 | $10.7M | Aug 12, 2026 | 1d |
| Richard R. DeLucaEvp&pres, Merck Animal Heallth | Sold · 2 lines | 11,699 | $131.63 | $1.5M | Aug 12, 2026 | 0d |
| Richard R. DeLucaEvp&pres, Merck Animal Heallth | Sold · 2 lines | 12,837 | $131.76 | $1.7M | Aug 11, 2026 | 1d |
| Richard R. DeLucaEvp&pres, Merck Animal Heallth | Sold | 20,784 | $130.43 | $2.7M | Aug 10, 2026 | 2d |
| Richard R. DeLucaEvp&pres, Merck Animal Heallth | Sold · 3 lines | 6,050 | $130.38 | $789K | Aug 6, 2026 | 4d |
| David R. MaraldoEVP & Pres. MMD | Sold | 2,686 | $128.72 | $346K | Aug 5, 2026 | 2d |
| David Michael WilliamsEvp,chief Info&digital Officer | Sold | 34,705 | $128.77 | $4.5M | Aug 5, 2026 | 2d |
| Chirfi GuindoEVP, Access, Policy & Comms | Sold | 15,000 | $131.00 | $2.0M | Aug 6, 2026 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in MRK
20 disclosures of 316 on record · median 28d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -2.1%S&P -0.1% · vs S&P 500 -1.9% | Aug 24, 2026 | Sep 4, 2026 | 11d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | +14.7%S&P -1.4% · vs S&P 500 +16.1% | Aug 7, 2026 | Sep 4, 2026 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +17.1%S&P +2.3% · vs S&P 500 +14.8% | Jul 8, 2026 | Aug 7, 2026 | 30d |
| Alan ArmstrongSelfFiled late | Stock | Sale (Full) | $15,001 - $50,000 | +23.3%S&P +20.2% · vs S&P 500 +3.1% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +27.6%S&P +0.4% · vs S&P 500 +27.2% | Jun 2, 2026 | Jul 6, 2026 | 34d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +28.1%S&P +1.6% · vs S&P 500 +26.5% | Jun 16, 2026 | Jul 6, 2026 | 20d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +32.5%S&P +3.2% · vs S&P 500 +29.3% | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | +26.0%S&P +12.6% · vs S&P 500 +13.5% | Mar 10, 2026 | Apr 7, 2026 | 28d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +24.7%S&P +11.1% · vs S&P 500 +13.6% | Feb 4, 2026 | Mar 16, 2026 | 40d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +36.5%S&P +10.0% · vs S&P 500 +26.4% | Jan 13, 2026 | Feb 11, 2026 | 29d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +46.5%S&P +12.7% · vs S&P 500 +33.8% | Dec 18, 2025 | Jan 15, 2026 | 28d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +45.9%S&P +11.7% · vs S&P 500 +34.3% | Dec 19, 2025 | Jan 12, 2026 | 24d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +53.0%S&P +15.5% · vs S&P 500 +37.5% | Nov 18, 2025 | Dec 15, 2025 | 27d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +58.8%S&P +13.4% · vs S&P 500 +45.3% | Nov 13, 2025 | Dec 11, 2025 | 28d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +67.9%S&P +11.4% · vs S&P 500 +56.5% | Oct 27, 2025 | Nov 10, 2025 | 14d |
| Val T. HoyleSpouse | Stock | Sale | $1,001 - $15,000 | +84.5%S&P +14.6% · vs S&P 500 +69.9% | Sep 23, 2025 | Oct 10, 2025 | 17d |
| Sheri BiggsSpouseFiled late | Stock | Sale | $15,001 - $50,000 | +56.9%S&P +34.4% · vs S&P 500 +22.5% | Mar 19, 2025 | Oct 5, 2025 | 200d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +87.7%S&P +14.9% · vs S&P 500 +72.9% | Sep 29, 2025 | Oct 3, 2025 | 4d |
| Val T. HoyleSpouseFiled late | Stock | Purchase | $1,001 - $15,000 | +42.2%S&P +31.1% · vs S&P 500 +11.2% | Oct 29, 2024 | Sep 12, 2025 | 318d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +82.6%S&P +21.4% · vs S&P 500 +61.2% | Aug 5, 2025 | Sep 12, 2025 | 38d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
25 of 27 listed · estimate, as of Sep 10, 202627 members report a position (estimated). The largest estimated position is in the $500,001 - $1,000,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| John W. Hickenlooper | Democrat · Senate | $500,001 - $1,000,000 | 2.3% |
| J. French Hill | Republican · House | $100,001 - $250,000 | 1.5% |
| Thomas H. Kean, Jr. | Republican · House | $100,001 - $250,000 | 2.6% |
| Kelly Morrison | Democrat · House | $100,001 - $250,000 | 0.7% |
| Kevin Hern | Republican · House | $100,001 - $250,000 | 0.4% |
| Robert Onder | Republican · House | $100,001 - $250,000 | 2.1% |
| Scott Franklin | Republican · House | $50,001 - $100,000 | 1.8% |
| Roger F. Wicker | Republican · Senate | $50,001 - $100,000 | 22.2% |
| Randy Fine | Republican · House | $50,001 - $100,000 | 3.0% |
| Gary C. Peters | Democrat · Senate | $15,001 - $50,000 | 1.3% |
| Gerald E. Connolly | Democrat · House | $15,001 - $50,000 | 5.4% |
| Susan M. Collins | Republican · Senate | $15,001 - $50,000 | 1.1% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $15,001 - $50,000 | 0.1% |
| Steve Cohen | Democrat · House | $15,001 - $50,000 | 1.2% |
| Marjorie Taylor Greene | Republican · House | $15,001 - $50,000 | 1.0% |
| Harriet M. Hageman | Republican · House | $15,001 - $50,000 | 0.7% |
| Shelley Moore Capito | Republican · Senate | $1,001 - $15,000 | 0.5% |
| Andy Harris | Republican · House | $1,001 - $15,000 | 64.4% |
| Daniel Meuser | Republican · House | $1,001 - $15,000 | 0.5% |
| Jeff Crank | Republican · House | $1,001 - $15,000 | 39.4% |
| Julie Johnson | Democrat · House | $1,001 - $15,000 | 0.1% |
| Michael A. Rulli | Republican · House | $1,001 - $15,000 | 1.1% |
| Rick Larsen | Democrat · House | $1,001 - $15,000 | 1.8% |
| Robert B. Aderholt | Republican · House | $1,001 - $15,000 | 1.4% |
| Sam Liccardo | Democrat · House | $1,001 - $15,000 | 1.3% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Jennifer ZacharyEVP, General Counsel | Option exercise | 54,927 | Aug 12, 2026 |
| David R. MaraldoEVP & Pres. MMD | Option exercise | 18,706 | Aug 5, 2026 |
| David Michael WilliamsEvp,chief Info&digital Officer | Option exercise | 52,847 | Aug 5, 2026 |
| Mary Ellen CoeDirector | Stock award | 233 | Jun 30, 2026 |
| Christine E. SeidmanDirector | Stock award | 63 | Jun 30, 2026 |
| Surendralal Lanca KarsanbhaiDirector | Stock award | 126 | Jun 30, 2026 |
| Stephen MayoDirector | Stock award | 1,853 | May 29, 2026 |
| Christine E. SeidmanDirector | Stock award | 1,853 | May 29, 2026 |
| Inge G. ThulinDirector | Stock award | 1,853 | May 29, 2026 |
| Thomas H. GlocerDirector | Stock award | 1,853 | May 29, 2026 |
| Risa J. Lavizzo-MoureyDirector | Stock award | 1,853 | May 29, 2026 |
| Douglas M. Baker Jr.Director | Stock award | 1,853 | May 29, 2026 |
| Kathy J. WardenDirector | Stock award | 1,853 | May 29, 2026 |
| Paul RothmanDirector | Stock award | 1,853 | May 29, 2026 |
| Mary Ellen CoeDirector | Stock award | 1,853 | May 29, 2026 |
| Patricia F. RussoDirector | Stock award | 1,853 | May 29, 2026 |
| Surendralal Lanca KarsanbhaiDirector | Stock award | 1,853 | May 29, 2026 |
| Pamela J. CraigDirector | Stock award | 1,853 | May 29, 2026 |
| David Michael WilliamsEvp,chief Info&digital Officer | Stock award | 18,222 | May 5, 2026 |
| Jennifer ZacharyEVP, General Counsel | Stock award | 47,376 | May 5, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling MRK?
Across the 9 most recent open-market filings shown here, 0 were purchases and 9 were sales.
Which members of Congress have traded MRK?
Ro Khanna, Alan Armstrong, Josh Gottheimer, Michael T. McCaul, Julie Johnson, Gilbert Ray Cisneros, Jr. and others disclosed MRK transactions in the filings shown here.
Which members of Congress hold MRK?
27 members of Congress report a position in MRK in the estimate we hold as of Sep 10, 2026. The three largest estimated positions belong to John W. Hickenlooper, J. French Hill and Thomas H. Kean, Jr.. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is MRK in the S&P 500 or the Nasdaq 100?
Merck & Co., Inc. is a current member of the S&P 500, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are MRK trades disclosed?
Insider filings on this page reached the public a median of 1 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.